The Orchard, Queens and Long Island City's Tallest Building by BLDG Management Co., Inc., Commences Leasing A New Icon Rises: Defined by a Landmark Collection of Refined Residences, Exceptional Design, and Unprecedented Amenities, including New York's Most Expansive Backyard GlobeNewswire January 12, 2026 A Media Snippet accompanying this announcement is available by clicking on this […]

COMSTOCK RESOURCES, INC. ANNOUNCES FOURTH QUARTER 2025 EARNINGS DATE AND CONFERENCE CALL INFORMATION GlobeNewswire January 12, 2026 FRISCO, TX, Jan. 12, 2026 (GLOBE NEWSWIRE) — Comstock Resources, Inc. (NYSE:CRK) plans to release its fourth quarter 2025 results on February 11, 2026 after the market closes and host its quarterly conference call at 10:00 a.m. CT

Westwood Announces Monthly Income Distributions for Westwood Salient Enhanced Midstream Income ETF (MDST) and Westwood Salient Enhanced Energy Income ETF (WEEI) GlobeNewswire January 12, 2026 DALLAS, Jan. 12, 2026 (GLOBE NEWSWIRE) — Westwood Holdings Group (WHG), a publicly-traded investment management boutique and wealth management firm, today announced monthly income distributions for Westwood Salient Enhanced Midstream

Gradalis Appoints Steven D. Weinstein as Chief Executive Officer GlobeNewswire January 12, 2026 Weinstein brings more than two decades of experience in life sciences leadership, venture capital, and company building Proven track record of guiding innovative healthcare organizations from early-stage development through commercialization DALLAS, Jan. 12, 2026 (GLOBE NEWSWIRE) — Gradalis, Inc., a clinical-stage biotechnology

Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones GlobeNewswire January 12, 2026 Advancing icovamenib toward late-stage clinical development in two Phase II clinical trials in patients with insulin-deficient type 2 diabetes (“T2D”) and in T2D patients currently failing glucagon-like peptide-1 (“GLP-1”) based therapies Successfully completed icovamenib food-effect study, establishing optimal dosing

Kahuna Labs Highlights New Constellation Research Report on Frontline Productivity and the Future of AI-Driven Decision Velocity GlobeNewswire January 12, 2026 SAN JOSE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) — Kahuna Labs today announced that it is promoting a newly published Constellation Research “Big Idea” report by founder and principal analyst R “Ray” Wang titled

Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress GlobeNewswire January 12, 2026 Two NDA submissions expected by mid-February 2026 for ulixacaltamide in essential tremor and relutrigine in SCN2A/8A-DEEs, both with Breakthrough Therapy Designation from the FDA Multiple registrational readouts expected across vormatrigine, relutrigine and elsunersen in 2026 Strong balance sheet,

WEBUY GLOBAL LTD. Expands Second Collaboration with CTG MICE Service Company Limited on AI Travel Devices GlobeNewswire January 12, 2026 Singapore, Jan. 12, 2026 (GLOBE NEWSWIRE) — WEBUY GLOBAL LTD (Nasdaq: WBUY) (the “Company” or “Webuy”) today announced an expanded collaboration with CTG MICE Service Company Limited, a subsidiary of China Tourism Group, to support

Copper Quest and i2i Enter Into Corporate Marketing and Investor Awareness Agreement GlobeNewswire January 12, 2026 VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) — Copper Quest Exploration Inc. (CSE: CQX; OTCQB: IMIMF; FRA: 3MX) (“Copper Quest” or the “Company“) is pleased to announce that it has entered into an agreement (the “Agreement“) with i2i

Profound Surpasses 2025 TULSA-PRO(R) Installed Base Goal Company's year-end TULSA-PRO installed base stood at 78 systems; qualified sales pipeline grew to 97 new systems GlobeNewswire January 12, 2026 TORONTO, Jan. 12, 2026 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided,